Kiora Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Kiora Pharmaceuticals has a total shareholder equity of $8.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $15.9M and $7.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$5.40m |
Equity | US$8.10m |
Total liabilities | US$7.79m |
Total assets | US$15.90m |
Recent financial health updates
Recent updates
Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement
Oct 13Kiora Pharma announces 1-for-40 reverse stock split
Sep 26Kiora Pharmaceuticals reports 1H results
Aug 12Kiora gets US patent for KIO-201 use with antibiotics for eye wound healing
Jul 28Kiora Pharmaceuticals prices $5.2M underwritten public offering
Jul 22Kiora begins enrolling in phase 2 trial of wound healing eye drops KIO-201
Jul 05EyeGate Pharmaceuticals announces $8M private placement
Jan 06EyeGate surge in premarket as it acquires Panoptes Pharma for $4M
Dec 21Financial Position Analysis
Short Term Liabilities: KPRX's short term assets ($7.0M) exceed its short term liabilities ($2.1M).
Long Term Liabilities: KPRX's short term assets ($7.0M) exceed its long term liabilities ($5.7M).
Debt to Equity History and Analysis
Debt Level: KPRX is debt free.
Reducing Debt: KPRX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KPRX has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: KPRX is forecast to have sufficient cash runway for 7 months based on free cash flow estimates, but has since raised additional capital.